US EditionRIVERMARK MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN RAPID III CLINICAL STUDY EVALUATING THE FLOSTENT™ SYSTEM
- Rivermark Medical announced the initial patient enrolled in its RAPID III study on April 23, 2025.
- The prospective trial assesses the FloStent System for treating benign prostatic hyperplasia symptoms.
- Sheldon Freedman, M.D., performed the first procedure at Freedman Urology in Las Vegas.
- Benign prostatic hyperplasia affects nearly "40 million men in the U.S.".
- Achieving this first patient enrollment represents a major milestone for Rivermark Medical.
Insights by Ground AI
Does this summary seem wrong?
23 Articles
23 Articles
All
Left
Center
7
Right
Denton Record-Chronicle+22 Reposted by 22 other sources
RIVERMARK MEDICAL ANNOUNCES FIRST PATIENT ENROLLED IN RAPID III CLINICAL STUDY EVALUATING THE FLOSTENT™ SYSTEM
Study to assess safety and effectiveness of a minimally invasive, zero-capital, outpatient device therapy for BPH
·Denton, United States
Read Full ArticleCoverage Details
Total News Sources23
Leaning Left0Leaning Right0Center7Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage